The injectable therapy setmelanotide, being developed by Rhythm Pharmaceuticals for Prader-Willi syndrome (PWS), curbs hyperphagia, or uncontrollable hunger, and reduces body weight in children and adults with obesity due to PWS. Those are the early findings of an exploratory Phase 2 clinical trial, ongoing at a single U.S.
News
Working closely with caregivers and clinical experts, an international team of scientists has adapted an eye-tracking test to more objectively measure the intense, constant hunger — called hyperphagia — that affects people with Prader-Willi syndrome (PWS). “By integrating stakeholder insights, we enhanced feasibility, accessibility and data quality,” demonstrating “the…
Sodium-glucose cotransporter-2 inhibitors (SGLT2is), a class of type 2 diabetes medications, may help improve blood sugar levels and support kidney health markers in adults with Prader-Willi syndrome (PWS) and type 2 diabetes, according to a study in France. Despite these benefits, the treatment did not lead to significant weight…
The experiences of siblings of individuals with Prader-Willi Syndrome (PWS) change as they age, as do their support needs, and are associated with variable parents’ perspectives, according to a recent study. Tailoring advice and support to the life stages of siblings, as well as involving them in discussions about…
Bright Minds Biosciences has launched a clinical program to evaluate whether its oral therapy candidate BMB-105 can ease hyperphagia, or insatiable hunger, and other behavioral symptoms in people with Prader-Willi syndrome (PWS). The experimental therapy targets the underlying disease mechanisms of PWS, and as such, is a “novel”…
Long-term treatment with human growth hormone, also known as somatropin, does not seem to influence mortality in people with Prader-Willi syndrome (PWS), but may increase the risk of developing type 2 diabetes, a study from South Korea found. The risk of type 2 diabetes increased by 6%…
Prader-Willi syndrome (PWS) is associated with shorter life expectancy, impaired quality of life, and high healthcare and caregiving costs — all of which place a heavy burden on families and the healthcare system. That’s according to a systematic review of more than 130 published studies. Data also found that…
Once-daily treatment with pitolisant is generally safe and helps reduce excessive daytime sleepiness (EDS) and abnormal behaviors in people with Prader-Willi syndrome (PWS) — notably with the repurposed therapy given at higher doses, and especially in children. That’s according to the full results of a proof-of-concept trial that tested two…
Soleno Therapeutics plans to help accelerate research toward finding a genetic cure for Prader-Willi syndrome (PWS). “We will commit up to $5 million in grants in the next year, where we will find the most promising genetic approaches to treat PWS, and find the ones where further significant investment…
Aardvark Therapeutics has amended the protocol for the Phase 3 HERO clinical trial testing ARD-101, its investigational oral therapy for excessive hunger associated with Prader-Willi Syndrome (PWS), to include patients as young as 10 years old. “Expansion of the Phase 3 HERO trial to include children 10 years…
Recent Posts
- PWS patients see weight loss, less hunger with setmelanotide in trial
- Eye-tracking test adapted to better measure hunger behaviors in PWS
- We struggled to find mental health support for our son with PWS
- How Prader-Willi families can enjoy the holiday season
- Diabetes medications may support kidney health in adults with PWS
- How parenting and caregiving have changed since we began
- Siblings of PWS patients require tailored support as they grow up
- Can BMB-105 ease insatiable hunger? PWS program to find out.
- My son’s first PWS camping trip was a success
- Lessons I’ve learned on my journey of caregiving